Kadcyla Approval History
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.
Development History and FDA Approval Process for Kadcyla
|May 3, 2019||FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer|
|Feb 22, 2013||FDA Approves Kadcyla for Late-Stage Breast Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.